Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
30. März 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial
16. November 2016 09:15 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - November 16, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has arrived at the door of U.S. FDA and awaits a pre-IND meeting with the agency. After years of surrounding its...
PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer
07. Juli 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - July 07, 2016) - PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, is being used in treatments for both cancer and...
PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
05. Mai 2016 09:15 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's...
PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process
06. April 2016 09:20 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - April 06, 2016) - PharmaCyte Biotech (OTCQB: PMCB) expects to begin its clinical trial in advanced pancreatic cancer in 2016; however, locking down an exact date has...
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
15. Oktober 2015 09:25 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - October 15, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli...
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
09. Oktober 2015 09:25 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has...
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
30. September 2015 09:30 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...
PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
03. Juni 2015 09:30 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate...
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
23. April 2015 09:20 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - April 23, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The...